EP4039247A3 - Formulation sublinguale de riluzole - Google Patents

Formulation sublinguale de riluzole Download PDF

Info

Publication number: EP4039247A3
Authority: EP; European Patent Office
Prior art keywords: riluzole; sublingual formulation; sublingual; disclosed; formulation
Prior art date: 2014-11-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP21169884.0A

Other languages

German (de)

English (en)

Other versions

EP4039247A2 (fr

Inventor

Vladimir Coric

Robert M. BERMAN

Ronald Samuel VLADYKA

Amgad SALEH

Danny Yu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Biohaven Pharmaceutical Holding Co Ltd

Original Assignee

Biohaven Pharmaceutical Holding Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-21

Filing date

2015-11-17

Publication date

2022-11-16

2015-11-17 Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd

2022-08-10 Publication of EP4039247A2 publication Critical patent/EP4039247A2/fr

2022-11-16 Publication of EP4039247A3 publication Critical patent/EP4039247A3/fr

Status Pending legal-status Critical Current

Links

FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 title abstract 4
229960004181 riluzole Drugs 0.000 title abstract 4
238000009472 formulation Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 3
238000000034 method Methods 0.000 abstract 2
206010031009 Oral pain Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Psychiatry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP21169884.0A 2014-11-21 2015-11-17 Formulation sublinguale de riluzole Pending EP4039247A3 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201462083094P	2014-11-21	2014-11-21
EP19186196.2A EP3616686B8 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole
PCT/US2015/061114 WO2016081472A1 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole
EP15823415.3A EP3220891B1 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole

Related Parent Applications (3)

Application Number	Title	Priority Date	Filing Date
EP15823415.3A Division EP3220891B1 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole
EP19186196.2A Division-Into EP3616686B8 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole
EP19186196.2A Division EP3616686B8 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole

Publications (2)

Publication Number	Publication Date
EP4039247A2 EP4039247A2 (fr)	2022-08-10
EP4039247A3 true EP4039247A3 (fr)	2022-11-16

Family

ID=55085882

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
EP19186196.2A Active EP3616686B8 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole
EP21169884.0A Pending EP4039247A3 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole
EP15823415.3A Active EP3220891B1 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP19186196.2A Active EP3616686B8 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
EP15823415.3A Active EP3220891B1 (fr)	2014-11-21	2015-11-17	Formulation sublinguale de riluzole

Country Status (24)

Country	Link
US (2)	US11660267B2 (fr)
EP (3)	EP3616686B8 (fr)
JP (3)	JP6753860B2 (fr)
KR (2)	KR20230135183A (fr)
CN (1)	CN107249567B (fr)
AU (2)	AU2015350148B2 (fr)
BR (1)	BR112017010423B1 (fr)
CA (1)	CA2967662A1 (fr)
CY (1)	CY1122469T1 (fr)
DK (1)	DK3220891T3 (fr)
EA (1)	EA038518B1 (fr)
ES (2)	ES2751300T3 (fr)
HR (1)	HRP20191892T8 (fr)
HU (1)	HUE046869T2 (fr)
IL (2)	IL252285B (fr)
LT (1)	LT3220891T (fr)
MX (1)	MX368838B (fr)
PH (1)	PH12017500934A1 (fr)
PL (1)	PL3220891T3 (fr)
PT (1)	PT3220891T (fr)
RS (1)	RS59490B1 (fr)
SG (1)	SG11201703896QA (fr)
SI (1)	SI3220891T1 (fr)
WO (1)	WO2016081472A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3038979A1 (fr)	2016-10-11	2018-04-19	Arvinas, Inc.	Composes et procedes pour la degradation ciblee du recepteur des androgenes
JP7354123B2 (ja)	2018-02-21	2023-10-02	エイアイ・セラピューティクス・インコーポレーテッド	アピリモドとグルタミン酸作動薬を用いた併用療法
EP3801626A4 (fr) *	2018-05-27	2022-02-23	Biohaven Pharmaceutical Holding Company Ltd.	Utilisation de comprimés orodispersibles à base de riluzole pour le traitement de maladies
CA3109769A1 (fr) *	2018-08-16	2020-02-20	Biohaven Therapeutics Ltd.	Utilisation de comprimes orodispersibles a base de riluzole pour le traitement de maladies
JP2022553954A (ja) *	2019-10-22	2022-12-27	アルビナス・オペレーションズ・インコーポレイテッド	前立腺癌を治療する方法
KR20230015933A (ko)	2020-05-09	2023-01-31	아비나스 오퍼레이션스, 인코포레이티드	이작용성 화합물, 이작용성 화합물의 초순수 형태, 및 이를 포함하는 투여 형태를 제조하는 방법
US20240016783A1 (en) *	2020-10-05	2024-01-18	Icahn School Of Medicine At Mount Sinai	Riluzole for the treatment of alzheimer's disease
US11672761B2 (en)	2020-11-16	2023-06-13	Orcosa Inc.	Rapidly infusing platform and compositions for therapeutic treatment in humans
CN113876735B (zh) *	2021-10-20	2023-05-12	陇南市第一人民医院	一种利鲁唑微球制剂及其制备方法
KR102625977B1 (ko)	2021-11-24	2024-01-17	부산대학교 산학협력단	리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010096869A1 (fr) *	2009-02-26	2010-09-02	Steven Michael Weiss	Agent permettant d'améliorer l'inotropie et la lusitropie et de traiter des maladies provoquant ou provoquées par une contractilité ou un relâchement médiocre du cœur
WO2010102923A2 (fr) *	2009-03-13	2010-09-16	Italfarmaco Spa	Suspensions aqueuses de riluzole
WO2016140878A2 (fr) *	2015-03-03	2016-09-09	Biohaven Pharmaceutical Holding Company Ltd.	Promédicaments de riluzole et leur procédé d'utilisation

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2492258A1 (fr) *	1980-10-17	1982-04-23	Pharmindustrie	Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
FR2702148B1 (fr) *	1993-03-05	1995-04-07	Rhone Poulenc Rorer Sa	Application d'anticonvulsivants dans le traitement du neuro-sida.
CA2166891C (fr)	1993-07-09	2001-07-03	Sang K. Wong	Methode pour l'obtention de formes posologiques par lyophylisation
US5457895A (en)	1993-10-01	1995-10-17	R. P. Scherer Corporation	Method of identifying freeze-dried dosage forms
US5837287A (en)	1994-10-28	1998-11-17	R P Scherer Corporation	Process for preparing solid pharmaceutical dosage forms
DE59711346D1 (de) *	1996-12-20	2004-04-01	Nutrinova Gmbh	Verfahren zur verstärkung der süsskraft und zur geschmacksverbesserung einer mischung hochintensiver süssstoffe
ES2318869T3 (es)	1997-02-20	2009-05-01	Massachusetts Institute Of Technology	Forma de dosificacion que presenta propiedades de dispersion rapida, metodos de uso y procedimiento para su fabricacion.
EP1001748B1 (fr)	1997-07-25	2006-04-19	Alpex Pharma S.A.	Procede de preparation de granules servant a produire des comprimes solubles dans la bouche a desintegration rapide
AU767154B2 (en)	1998-11-20	2003-10-30	Skyepharma Canada Inc.	Dispersible phospholipid stabilized microparticles
EP1135105B1 (fr) *	1998-12-09	2005-03-02	Chiron Corporation	Utilisation d'un agent neurologique pour la preparation d'un medicament pour le traitement d'une maladie du systeme nerveux central
FR2787028B1 (fr) *	1998-12-15	2002-10-18	Aventis Pharma Sa	Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6284270B1 (en)	1999-08-04	2001-09-04	Drugtech Corporation	Means for creating a mass having structural integrity
US6316029B1 (en)	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
JP2001328947A (ja) *	2000-05-19	2001-11-27	Ritsuko Senba	脳由来神経栄養因子発現促進剤
US6432992B1 (en) *	2000-06-05	2002-08-13	Aventis Pharm Sa	Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6982251B2 (en)	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en)	2000-12-29	2004-11-09	Mcneil-Ppc, Inc.	Process for preparing a soft tablet
US6509040B1 (en)	2001-06-22	2003-01-21	R.P. Scherer Corporation	Fast dispersing dosage forms essentially free of mammalian gelatin
AU2002334939A1 (en)	2001-10-12	2003-04-22	Eugene R. Cooper	Compositions having a combination of particles for immediate release and for controlled release
CA2476250C (fr)	2002-02-13	2010-08-03	Michael K. Weibel	Forme posologique medicamenteuse et procede de fabrication
EP2316468A1 (fr) *	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
WO2004105756A2 (fr) *	2003-05-29	2004-12-09	Novartis Ag	Combinaison contenant un agent neuroprotecteur et un agent se fixant a la gadph, et utilisation pharmaceutique associee
US7282217B1 (en)	2003-08-29	2007-10-16	Kv Pharmaceutical Company	Rapidly disintegrable tablets
CA2558380A1 (fr) *	2004-03-03	2005-09-15	Teva Pharmaceutical Industries, Ltd.	Therapie de combinaison avec acetate de glatiramer et riluzole
US8158152B2 (en)	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
BRPI0620578A2 (pt)	2005-12-27	2011-12-06	Jubilant Organosys Ltd	composição farmacêutica que dissolve na boca e processo para o preparo da mesma
GB0625322D0 (en) *	2006-12-19	2007-01-24	Pharmakodex Ltd	Pharmaceutical compositions
EP1980240A1 (fr)	2007-04-11	2008-10-15	Cephalon France	Composition pharmaceutique lyophilisée et leurs procédés de fabrication et d'utilisation
WO2009002084A2 (fr)	2007-06-27	2008-12-31	Hanmi Pharm. Co., Ltd.	Procédé de préparation d'une formulation à désagrégation rapide pour l'administration par voie orale et appareil de préparation et de conditionnement correspondant
US20110183942A1 (en) *	2008-07-15	2011-07-28	University Of Medicine And Dentistry Of New Jersey	Methods and Compositions for Treating Alzheimer's Disease
US8256233B2 (en)	2008-10-31	2012-09-04	The Invention Science Fund I, Llc	Systems, devices, and methods for making or administering frozen particles
US8545806B2 (en)	2008-10-31	2013-10-01	The Invention Science Fund I, Llc	Compositions and methods for biological remodeling with frozen particle compositions
US8313768B2 (en)	2009-09-24	2012-11-20	Mcneil-Ppc, Inc.	Manufacture of tablet having immediate release region and sustained release region
UA113165C2 (xx) *	2011-03-01	2016-12-26		Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US9241933B2 (en)	2011-03-01	2016-01-26	Pharnext	Compositions for treating amyotrophic lateral sclerosis
DK2560631T3 (da) *	2011-03-01	2014-02-10	Pharnext	Baclofen- og acamprosat-baseret af neurologiske forstyrrelser
WO2013010015A2 (fr) *	2011-07-13	2013-01-17	Cytokinetics, Inc.	Polythérapie pour als
IN2014DN07989A (fr)	2012-03-01	2015-05-01	Pharnext
CN107735077A (zh)	2014-11-21	2018-02-23	拜尔哈文制药股份有限公司	利鲁唑的舌下给药

2015
- 2015-11-17 DK DK15823415T patent/DK3220891T3/da active
- 2015-11-17 AU AU2015350148A patent/AU2015350148B2/en active Active
- 2015-11-17 ES ES15823415T patent/ES2751300T3/es active Active
- 2015-11-17 KR KR1020237031525A patent/KR20230135183A/ko not_active Application Discontinuation
- 2015-11-17 KR KR1020177016906A patent/KR102580378B1/ko active IP Right Grant
- 2015-11-17 PL PL15823415T patent/PL3220891T3/pl unknown
- 2015-11-17 HU HUE15823415A patent/HUE046869T2/hu unknown
- 2015-11-17 LT LT15823415T patent/LT3220891T/lt unknown
- 2015-11-17 SG SG11201703896QA patent/SG11201703896QA/en unknown
- 2015-11-17 EP EP19186196.2A patent/EP3616686B8/fr active Active
- 2015-11-17 WO PCT/US2015/061114 patent/WO2016081472A1/fr active Application Filing
- 2015-11-17 EP EP21169884.0A patent/EP4039247A3/fr active Pending
- 2015-11-17 RS RS20191376A patent/RS59490B1/sr unknown
- 2015-11-17 BR BR112017010423-7A patent/BR112017010423B1/pt active IP Right Grant
- 2015-11-17 JP JP2017545858A patent/JP6753860B2/ja active Active
- 2015-11-17 CN CN201580073630.4A patent/CN107249567B/zh active Active
- 2015-11-17 EP EP15823415.3A patent/EP3220891B1/fr active Active
- 2015-11-17 MX MX2017006446A patent/MX368838B/es active IP Right Grant
- 2015-11-17 US US15/100,160 patent/US11660267B2/en active Active
- 2015-11-17 PT PT158234153T patent/PT3220891T/pt unknown
- 2015-11-17 CA CA2967662A patent/CA2967662A1/fr active Pending
- 2015-11-17 SI SI201530956T patent/SI3220891T1/sl unknown
- 2015-11-17 ES ES19186196T patent/ES2882783T3/es active Active
- 2015-11-17 EA EA201790958A patent/EA038518B1/ru unknown
2017
- 2017-05-15 IL IL252285A patent/IL252285B/en active IP Right Grant
- 2017-05-19 PH PH12017500934A patent/PH12017500934A1/en unknown
2019
- 2019-10-18 HR HRP20191892TT patent/HRP20191892T8/hr unknown
- 2019-10-22 CY CY20191101095T patent/CY1122469T1/el unknown
2020
- 2020-08-20 JP JP2020139429A patent/JP2021001173A/ja active Pending
- 2020-10-20 IL IL278188A patent/IL278188A/en unknown
- 2020-10-25 US US17/079,498 patent/US20210038499A1/en active Pending
2021
- 2021-02-17 AU AU2021201034A patent/AU2021201034B2/en active Active
2023
- 2023-02-03 JP JP2023015640A patent/JP2023065398A/ja active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010096869A1 (fr) *	2009-02-26	2010-09-02	Steven Michael Weiss	Agent permettant d'améliorer l'inotropie et la lusitropie et de traiter des maladies provoquant ou provoquées par une contractilité ou un relâchement médiocre du cœur
WO2010102923A2 (fr) *	2009-03-13	2010-09-16	Italfarmaco Spa	Suspensions aqueuses de riluzole
WO2016140878A2 (fr) *	2015-03-03	2016-09-09	Biohaven Pharmaceutical Holding Company Ltd.	Promédicaments de riluzole et leur procédé d'utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Riluzole in Mild Alzheimer's Disease Study: NCT01703117", 21 November 2013 (2013-11-21), XP055965242, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT01703117?V_3=View#StudyPageTop> [retrieved on 20220927] *
REED M N: "The role of the tripartite glutamatergic synapse in the pathophysiology of Alzheimer's disease", 44TH ANNU MEET SOC NEUROSCI, 16 November 2014 (2014-11-16), XP055965232, Retrieved from the Internet <URL:https://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=e5ed7920-d623-41df-be15-f16360644d04&cKey=5d515aae-d80c-46fb-a950-909ddcb7d904&mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7> *
WEITZNER D.: "Riluzole attenuates spatial memory deficits in a TauP301L mouse model of Alzheimer's disease", 44TH ANNU MEET SOC NEUROSCI, 15 November 2014 (2014-11-15), XP055965230, Retrieved from the Internet <URL:https://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3527&sKey=a7fe65d1-e9f1-4a0d-976f-a57be5b3955a&cKey=f51e058a-67b5-4c8a-9c86-4ca6b563a000&mKey=54c85d94-6d69-4b09-afaa-502c0e680ca7#> *

Also Published As

Publication number	Publication date
HRP20191892T1 (hr)	2020-01-10
IL278188A (en)	2020-11-30
US20210038499A1 (en)	2021-02-11
EP3616686B8 (fr)	2021-06-23
AU2021201034B2 (en)	2023-07-06
BR112017010423B1 (pt)	2023-09-26
US11660267B2 (en)	2023-05-30
EP3220891A1 (fr)	2017-09-27
WO2016081472A1 (fr)	2016-05-26
HRP20191892T8 (hr)	2020-09-18
EP4039247A2 (fr)	2022-08-10
SI3220891T1 (sl)	2020-02-28
CY1122469T1 (el)	2021-01-27
MX2017006446A (es)	2018-02-12
LT3220891T (lt)	2019-11-11
JP2021001173A (ja)	2021-01-07
MX368838B (es)	2019-10-18
HUE046869T2 (hu)	2020-04-28
ES2751300T3 (es)	2020-03-31
AU2015350148B2 (en)	2020-11-26
RS59490B1 (sr)	2019-12-31
IL252285B (en)	2020-10-29
CN107249567A (zh)	2017-10-13
KR102580378B1 (ko)	2023-09-19
JP6753860B2 (ja)	2020-09-09
EA038518B1 (ru)	2021-09-09
EP3616686B1 (fr)	2021-05-19
PT3220891T (pt)	2019-10-31
IL252285A0 (en)	2017-07-31
US20180153794A1 (en)	2018-06-07
BR112017010423A2 (pt)	2017-12-26
JP2023065398A (ja)	2023-05-12
AU2015350148A1 (en)	2017-06-15
SG11201703896QA (en)	2017-06-29
EP3616686A1 (fr)	2020-03-04
EA201790958A1 (ru)	2018-01-31
CA2967662A1 (fr)	2016-05-26
EP3220891B1 (fr)	2019-07-24
PL3220891T3 (pl)	2020-08-24
AU2021201034A1 (en)	2021-03-11
JP2017535613A (ja)	2017-11-30
KR20170137032A (ko)	2017-12-12
DK3220891T3 (da)	2019-11-04
KR20230135183A (ko)	2023-09-22
ES2882783T3 (es)	2021-12-02
PH12017500934A1 (en)	2017-11-20
CN107249567B (zh)	2021-08-03

Legal Events

Date	Code	Title	Description
2022-07-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2022-07-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2022-08-10	AC	Divisional application: reference to earlier application	Ref document number: 3220891 Country of ref document: EP Kind code of ref document: P Ref document number: 3616686 Country of ref document: EP Kind code of ref document: P
2022-08-10	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-10-14	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2022-11-16	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-11-16	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 25/30 20060101ALI20221007BHEP Ipc: A61P 25/28 20060101ALI20221007BHEP Ipc: A61P 25/24 20060101ALI20221007BHEP Ipc: A61P 25/22 20060101ALI20221007BHEP Ipc: A61P 25/18 20060101ALI20221007BHEP Ipc: A61P 25/16 20060101ALI20221007BHEP Ipc: A61P 25/00 20060101ALI20221007BHEP Ipc: A61K 47/26 20060101ALI20221007BHEP Ipc: A61K 47/20 20060101ALI20221007BHEP Ipc: A61K 31/428 20060101ALI20221007BHEP Ipc: A61K 9/20 20060101ALI20221007BHEP Ipc: A61K 9/08 20060101ALI20221007BHEP Ipc: A61K 9/00 20060101AFI20221007BHEP
2023-03-03	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40077183 Country of ref document: HK
2023-05-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2023-06-21	17P	Request for examination filed	Effective date: 20230516
2023-06-21	RBV	Designated contracting states (corrected)	Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-10-26	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2023-11-29	17Q	First examination report despatched	Effective date: 20231025

Publication	Publication Date	Title
EP4039247A3 (fr)	2022-11-16	Formulation sublinguale de riluzole
PH12017500933A1 (en)	2017-11-20	Sublingual administration of riluzole
MX2018004947A (es)	2018-11-09	Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
MX2017004471A (es)	2017-11-20	Compuestos de triazolopiridina y métodos para el tratamiento de fibrosis cística.
MX2016011105A (es)	2016-12-12	Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EP4289822A3 (fr)	2024-01-24	Benzoimidazol-1,2-yl amides en tant qu'activateurs du canal kv7
NZ744323A (en)	2020-08-28	Compositions comprising 15-hepe and methods of using the same
PH12016502530A1 (en)	2017-04-10	Pharmaceutical compositions comprising dgla and use of same
PH12016502233A1 (en)	2017-02-06	(s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016501483B1 (en)	2016-08-22	P-substituted asymmetric ureas and medical uses thereof
WO2016080796A3 (fr)	2016-10-06	Composition pharmaceutique contenant un composé sesquiterpénique et utilisable en vue de la prévention ou du traitement de maladies à médiation par stat3, et son utilisation
TW201613639A (en)	2016-04-16	Methods for treating cardiovascular diseases
PH12016502236A1 (en)	2017-02-06	(r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
IL248428B (en)	2020-11-30	3,1-propanedisulfonic acid or its pharmaceutically acceptable salt for use in the treatment of sarcoidosis
MX2018006631A (es)	2019-01-30	Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
WO2016082807A3 (fr)	2016-07-21	Nouvelle utilisation d'itraconazole
MA39009A (fr)	2015-09-16	Compositions pharmaceutiques comprenant un agent actif
RU2014154366A (ru)	2016-07-20	Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
IL260009B (en)	2021-06-30	Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease
EP4335508A3 (fr)	2024-07-10	(+)-azasetron destiné à être utilisé dans le traitement de troubles de l'oreille
WO2016073652A8 (fr)	2017-05-04	Iminosucres utiles pour le traitement de maladies virales
MX2016010919A (es)	2016-11-29	4-bencilsulfonil-2-butenonitrilo.
UA104614U (uk)	2016-02-10	Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих
ITUB20153076A1 (it)	2017-02-11	Composti farmaceuticamente attivi per l?impiego nel trattamento terapeutico di disturbi del movimento.
UA108139U (uk)	2016-07-11	Спосіб терапії корів з ендометритом, як профілактика гонадопатій